Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegmolesatide versus recombinant human erythropoietin for renal anemia in chronic kidney disease
ChiCTR2500099329Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Mar 2025
- Modality
- PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of peglmolesatide in anemia of renal disease and chronic kidney disease (CKD) (3 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Blood routine examination, Serum creatinine and 6 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
peglmolesatide
03
Conditions
anemia of renal diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500099329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099329.